JP2004511213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004511213A5 JP2004511213A5 JP2002500948A JP2002500948A JP2004511213A5 JP 2004511213 A5 JP2004511213 A5 JP 2004511213A5 JP 2002500948 A JP2002500948 A JP 2002500948A JP 2002500948 A JP2002500948 A JP 2002500948A JP 2004511213 A5 JP2004511213 A5 JP 2004511213A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57992700A | 2000-05-26 | 2000-05-26 | |
| US21406500P | 2000-06-26 | 2000-06-26 | |
| PCT/US2001/017139 WO2001092337A2 (en) | 2000-05-26 | 2001-05-23 | Soluble ctla4 mutant molecules and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004511213A JP2004511213A (ja) | 2004-04-15 |
| JP2004511213A5 true JP2004511213A5 (enExample) | 2005-12-22 |
| JP4328525B2 JP4328525B2 (ja) | 2009-09-09 |
Family
ID=26908652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002500948A Expired - Lifetime JP4328525B2 (ja) | 2000-05-26 | 2001-05-23 | 可溶性ｃｔｌａ４突然変異体分子およびその用途 |
Country Status (41)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| CA2413190C (en) | 2000-07-03 | 2009-04-07 | Bristol-Myers Squibb Company | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| ATE390931T1 (de) | 2001-05-23 | 2008-04-15 | Bristol Myers Squibb Co | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen |
| AU2003243152A1 (en) * | 2002-04-19 | 2003-11-03 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
| DE10232697A1 (de) * | 2002-07-15 | 2004-02-05 | Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin | Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen |
| BR0317723A (pt) | 2002-12-23 | 2005-11-22 | Bristol Myers Squibb Co | Processo de cultura de células de mamìfero para a produção de proteìna |
| KR101088223B1 (ko) * | 2002-12-23 | 2011-11-30 | 브리스톨-마이어스 스큅 컴퍼니 | 단백질 생산을 위한 포유류 세포 배양 방법에서의 생산물품질 향상 |
| AU2003299971A1 (en) | 2002-12-30 | 2004-07-29 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| CA2543484C (en) | 2003-10-27 | 2014-02-04 | Amgen Inc. | Modulation of immune response to an immunogen with ctla-4 and tnfbp |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| TWI423986B (zh) | 2005-12-20 | 2014-01-21 | 必治妥美雅史谷比公司 | 組合物及製造組合物之方法 |
| US7510844B2 (en) | 2006-01-24 | 2009-03-31 | Bristol-Myers Squibb Company | CD86 and CD80 receptor competition assays |
| WO2008005290A2 (en) | 2006-06-29 | 2008-01-10 | The Trustees Of Columbia University In The City Of New York | Methods for testing anti-thrombotic agents |
| GB0620934D0 (en) | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| CA2832111A1 (en) | 2006-12-20 | 2008-07-03 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
| DK2222697T3 (da) | 2007-11-01 | 2013-03-11 | Perseid Therapeutics Llc | Immunsuppressive polypeptider og nukleinsyrer |
| HRP20180045T1 (hr) * | 2008-10-02 | 2018-03-23 | Aptevo Research And Development Llc | Proteini antagonisti cd86 koji se vežu na više meta |
| US9540426B2 (en) * | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| WO2011113019A2 (en) | 2010-03-12 | 2011-09-15 | Abbott Biotherapeutics Corp. | Ctla4 proteins and their uses |
| MX2013009741A (es) | 2011-02-23 | 2014-01-17 | Amgen Inc | Medio de cultivo celular para exposicion a uvc y metodos relacionados al mismo. |
| WO2013010537A1 (en) | 2011-07-20 | 2013-01-24 | Aarhus Universitet | Method of treating morphea |
| US9758566B2 (en) | 2012-03-29 | 2017-09-12 | The General Hospital Corporation | Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4) |
| SG10201609447XA (en) * | 2012-05-11 | 2017-01-27 | Medimmune Llc | Ctla-4 variants |
| US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| CN113138279A (zh) * | 2012-06-27 | 2021-07-20 | 法姆制药有限责任公司 | 融合蛋白组合物的应用 |
| US20140112958A1 (en) | 2012-10-24 | 2014-04-24 | Mwm Biomodels Gmbh | Pancreatic islets of transgenic LEA29Y animals for treating diabetes |
| CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
| SG10201806643WA (en) | 2014-01-13 | 2018-09-27 | Amgen Inc | Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins |
| GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| ES2909630T3 (es) | 2014-06-04 | 2022-05-09 | Amgen Inc | Métodos de recolección en cultivos de células de mamífero |
| EP3227454B1 (en) | 2014-12-01 | 2020-01-29 | Amgen Inc. | Process for manipulating the level of glycan content of a glycoprotein |
| WO2016130734A1 (en) | 2015-02-11 | 2016-08-18 | Bristol-Myers Squibb Company | Use of phenolic antioxidants in cell culture for the production of proteins |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| CA2997947A1 (en) | 2015-09-09 | 2017-03-16 | The Trustees Of Columbia University In The City Of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
| JP2018536404A (ja) | 2015-11-09 | 2018-12-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法 |
| CA3036997A1 (en) | 2016-09-19 | 2018-03-22 | Oncoimmune, Inc. | Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy |
| CN107987153A (zh) * | 2016-10-27 | 2018-05-04 | 广东香雪精准医疗技术有限公司 | 高亲和力的可溶性pd-1分子 |
| US12058986B2 (en) | 2017-04-20 | 2024-08-13 | Egenesis, Inc. | Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| EP3735417A1 (en) | 2018-01-03 | 2020-11-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN109453383A (zh) * | 2018-11-12 | 2019-03-12 | 陈慧慧 | 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用 |
| CN115551530A (zh) | 2019-08-27 | 2022-12-30 | 通尼克斯制药有限公司 | 经修饰的tff2多肽 |
| JP2022548197A (ja) | 2019-12-06 | 2022-11-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｖｅｇｆタンパク質組成物及びその製造方法 |
| CN115803009A (zh) | 2020-05-08 | 2023-03-14 | 瑞泽恩制药公司 | 用于治疗眼病和癌症的vegf阱和微阱及方法 |
| JP2023530712A (ja) | 2020-06-18 | 2023-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 未処理ｃ末端リジンを正確に測定するための重ペプチドアプローチ |
| JP2023537670A (ja) | 2020-07-28 | 2023-09-05 | シージェン インコーポレイテッド | ポリペプチドを生産するための方法及びシステム |
| KR20240125949A (ko) | 2021-12-16 | 2024-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | 바이러스 불활성화를 위한 세제 |
| KR20240168482A (ko) | 2022-03-02 | 2024-11-29 | 리제너론 파아마슈티컬스, 인크. | 항체 생산을 위한 세포 배양 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| DK0606217T4 (da) * | 1991-06-27 | 2009-03-30 | Bristol Myers Squibb Co | CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| JP3521382B2 (ja) * | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| GB9809280D0 (en) * | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
| JP2003532370A (ja) * | 1998-10-07 | 2003-11-05 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 新規なＴｈ２特異的分子およびその使用方法 |
| CA2413190C (en) * | 2000-07-03 | 2009-04-07 | Bristol-Myers Squibb Company | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
-
2001
- 2001-05-23 EP EP15197082.9A patent/EP3029062A1/en not_active Withdrawn
- 2001-05-23 KR KR1020077017691A patent/KR100889887B1/ko not_active Expired - Lifetime
- 2001-05-23 MX MXPA02011534A patent/MXPA02011534A/es active IP Right Grant
- 2001-05-23 PT PT01937764T patent/PT1248802E/pt unknown
- 2001-05-23 ES ES04008908T patent/ES2571852T3/es not_active Expired - Lifetime
- 2001-05-23 SI SI200130186T patent/SI1248802T1/xx unknown
- 2001-05-23 AU AU6346601A patent/AU6346601A/xx active Pending
- 2001-05-23 HU HU0302201A patent/HU228137B1/hu active Protection Beyond IP Right Term
- 2001-05-23 EE EEP200200659A patent/EE05458B1/xx active Protection Beyond IP Right Term
- 2001-05-23 EP EP04008908.8A patent/EP1536234B1/en not_active Expired - Lifetime
- 2001-05-23 AT AT01937764T patent/ATE271066T1/de active
- 2001-05-23 ES ES01937764T patent/ES2225549T3/es not_active Expired - Lifetime
- 2001-05-23 IL IL152315A patent/IL152315A/en active Protection Beyond IP Right Term
- 2001-05-23 DK DK01937764T patent/DK1248802T3/da active
- 2001-05-23 TW TW097137809A patent/TWI319405B/zh not_active IP Right Cessation
- 2001-05-23 EG EG20010548A patent/EG24459A/xx active
- 2001-05-23 KR KR1020027015946A patent/KR100895134B1/ko not_active Expired - Lifetime
- 2001-05-23 CZ CZ2002-3892A patent/CZ304451B6/cs unknown
- 2001-05-23 UY UY26723A patent/UY26723A1/es not_active IP Right Cessation
- 2001-05-23 UA UA20021210563A patent/UA87432C2/uk unknown
- 2001-05-23 HK HK03100239.8A patent/HK1048126B/en not_active IP Right Cessation
- 2001-05-23 AR ARP010102449A patent/AR031699A1/es active IP Right Grant
- 2001-05-23 TW TW090112431A patent/TWI314933B/zh not_active IP Right Cessation
- 2001-05-23 CA CA002409748A patent/CA2409748C/en not_active Expired - Lifetime
- 2001-05-23 PL PL366231A patent/PL206267B1/pl unknown
- 2001-05-23 RU RU2002131588/13A patent/RU2283847C2/ru active Protection Beyond IP Right Term
- 2001-05-23 EE EEP201100050A patent/EE05557B1/xx unknown
- 2001-05-23 GE GE4987A patent/GEP20053658B/en unknown
- 2001-05-23 BR BR0111191-4 patent/BRPI0111191B8/pt not_active IP Right Cessation
- 2001-05-23 SK SK1570-2002A patent/SK288131B6/sk not_active IP Right Cessation
- 2001-05-23 CN CNA2007100840790A patent/CN101255192A/zh active Pending
- 2001-05-23 TR TR2004/02703T patent/TR200402703T4/xx unknown
- 2001-05-23 DE DE60104282T patent/DE60104282T2/de not_active Expired - Lifetime
- 2001-05-23 CN CNB018101453A patent/CN1309735C/zh not_active Expired - Lifetime
- 2001-05-23 JP JP2002500948A patent/JP4328525B2/ja not_active Expired - Lifetime
- 2001-05-23 WO PCT/US2001/017139 patent/WO2001092337A2/en not_active Ceased
- 2001-05-23 MY MYPI20012427A patent/MY136113A/en unknown
- 2001-05-23 EP EP01937764A patent/EP1248802B9/en not_active Expired - Lifetime
- 2001-05-23 AU AU2001263466A patent/AU2001263466C1/en active Active
- 2001-05-23 PE PE2001000465A patent/PE20011338A1/es active IP Right Grant
-
2002
- 2002-11-04 ZA ZA200208944A patent/ZA200208944B/en unknown
- 2002-11-13 LT LT2002114A patent/LT5133B/lt not_active IP Right Cessation
- 2002-11-25 NO NO20025656A patent/NO330797B1/no not_active IP Right Cessation
- 2002-11-26 EC EC2002004365A patent/ECSP024365A/es unknown
- 2002-12-19 LV LVP-02-214A patent/LV12994B/en unknown
-
2011
- 2011-11-10 BE BE2011C041C patent/BE2011C041I2/fr unknown
- 2011-11-16 LU LU91902C patent/LU91902I2/fr unknown
- 2011-12-05 DE DE201112100063 patent/DE122011100063I1/de active Pending
- 2011-12-07 FR FR11C0053C patent/FR11C0053I2/fr active Active
- 2011-12-12 CY CY2011019C patent/CY2011019I1/el unknown
- 2011-12-15 NO NO2011027C patent/NO2011027I1/no not_active IP Right Cessation
-
2013
- 2013-04-12 HU HUS1300012C patent/HUS1300012I1/hu unknown
-
2016
- 2016-06-10 CY CY20161100511T patent/CY1117625T1/el unknown